SynAct Pharma AB (“SynAct”) today announced that all members of its board and executive management have agreed to a lock-up arrangement for their shares in the company until December 31, 2025. In total, these lock-up agreements correspond to 6.9% percent of the votes and capital in SynAct Pharma.

The lock-up prevents the selling of shares while being a member of the Board and the executive management, including majority holdings in companies owning shares in SynAct, except what is reasonably needed to cover tax payments applicable for Danish holding companies.

“The members of the board and the entire management team reconfirms their commitments to the future development of the company and have no intention of selling their shares now,” said Jeppe Øvlesen, CEO of SynAct Pharma.

For further information about SynAct Pharma AB, please contact: Jeppe Øvlesen

CEO, SynAct Pharma AB
Phone: +45 28 44 75 67
Mail: joo@synactpharma.com

About SynAct Pharma AB
SynAct Pharma AB (publ) (Nasdaq Stockholm: SYNACT) is a clinical stage biotechnology company focused on resolving inflammation through selective activation of the melanocortin system. The company has a broad portfolio of oral and injectable selective melanocortin agonists aimed at inducing anti-inflammatory and anti-inflammatory activity in autoimmune and inflammatory diseases to help patients achieve immune balance and overcome their inflammation. For more information: www.synactpharma.com.

Attachments
SynAct Pharma’s board and management enter into lock-up agreements

Läs mer på MFN